الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
• Vascular endothelial growth factors have been extensively studied over the past few years.For patients with diabetic retinopathy, VEGF inhibitors seemed to be more effective as a short-term treatment option than alternative therapies, however, the evidence is not of sufficient quality to confirm safety. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) xafter single or multiple intravitreal injections of these protein-based therapeutics, whereas, the true mechanism leading to inflammation and sustained spikes in IOP remains unknown.
• In addition, it has been recorded that, serial injections of anti-VEGF agents might lead to persistent IOP elevations, whereas, the clinician should recognize this phenomenon, as it can occur even if the patient has tolerated multiple prior injections without IOP elevation. Prolonged monitoring of IOP might not be necessary on the day of injection in most cases, however, cautious monitoring should be considered in selected cases.
• Our study was conducted to evaluate changes in intraocular pressure following intravitreal injections of different types of anti-VEGF agents. In one group (group A), 50 eyes were scheduled for intravitreal ranibizumab of (0.5 mg/0.05 ml), the second group(group B): 50 eyes were scheduled for intravitreal bevacizumab of (1.25 mg/0.05 ml). We conclude that intra ocular pressure (IOP) was flactuated after intraviteal ranibizumab & bevacizumab within normal level in the follow up one day, one week and one month after injection.